BlackRock
CLDI icon

BlackRock’s Calidi Biotherapeutics CLDI Stock Holding History

BlackRock’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22
Closed -$60 – 5474
2025
Q2 		$60 Hold
22
– – ﹤0.01% 5419
2025
Q1 		$147 Hold
22
– – ﹤0.01% 5375
2024
Q4 		$298 Hold
22
– – ﹤0.01% 5339
2024
Q3 		$295 Hold
22
– – ﹤0.01% 5168
2024
Q2 		$518 Hold
22
– – ﹤0.01% 5217
2024
Q1 		$1.46K Hold
22
– – ﹤0.01% 5191
2023
Q4 		$3.91K Buy
+22
New +$5.9K ﹤0.01% 5206

Other funds holding CLDI

HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

BlackRock's CLDI Position: Q3 2025 in Review

BlackRock sold out of Calidi Biotherapeutics (CLDI) in Q3 2025, closing a stake of 22 shares — an estimated $60 sold.

BlackRock first reported a position in CLDI in Q4 2023 and held it in 7 quarters. The position peaked at $3.91K in Q4 2023. 22 funds tracked by Wall St. Rank hold CLDI as of Q3 2025.

  • BlackRock reported no remaining Calidi Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • BlackRock sold 22 Calidi Biotherapeutics shares in Q3 2025, an estimated $60.
  • BlackRock first reported a position in Calidi Biotherapeutics in Q4 2023 and held it in 7 quarters.
  • BlackRock's Calidi Biotherapeutics position peaked at $3.91K in Q4 2023.
  • 22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2025.

Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.